ESPR Quote, Financials, Valuation and Earnings

Heron Therapeutics has a net margin of -62.24% compared to Esperion Therapeutics's net margin of 6.77%. Esperion Therapeutics's return on equity of -- beat Heron Therapeutics's return on equity of --.

Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 366.59%. On the other hand Heron Therapeutics has an analysts' consensus of $6.25 which suggests that it could grow by 212.5%. Given that Esperion Therapeutics has higher upside potential than Heron Therapeutics, analysts believe Esperion Therapeutics is more attractive than Heron Therapeutics.

Esperion Therapeutics has a beta of 0.703, which suggesting that the stock is 29.654% less volatile than S&P 500. In comparison Heron Therapeutics has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.163%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Heron Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Heron Therapeutics pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $65M, which are larger than Heron Therapeutics quarterly revenues of $38.9M. Esperion Therapeutics's net income of -$40.5M is lower than Heron Therapeutics's net income of $2.6M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Heron Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.93x versus 2.06x for Heron Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -62.24% compared to Esperion Therapeutics's net margin of -111.65%. Esperion Therapeutics's return on equity of -- beat Ionis Pharmaceuticals's return on equity of -100.15%.

Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 366.59%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $58.30 which suggests that it could grow by 38.26%. Given that Esperion Therapeutics has higher upside potential than Ionis Pharmaceuticals, analysts believe Esperion Therapeutics is more attractive than Ionis Pharmaceuticals.

Esperion Therapeutics has a beta of 0.703, which suggesting that the stock is 29.654% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.230, suggesting its less volatile than the S&P 500 by 77.021%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $65M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $131.6M. Esperion Therapeutics's net income of -$40.5M is higher than Ionis Pharmaceuticals's net income of -$146.9M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.93x versus 8.98x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -62.24% compared to Esperion Therapeutics's net margin of -598.74%. Esperion Therapeutics's return on equity of -- beat Ocular Therapeutix's return on equity of -56.05%.

Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 366.59%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.92 which suggests that it could grow by 57.44%. Given that Esperion Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Esperion Therapeutics is more attractive than Ocular Therapeutix.

Esperion Therapeutics has a beta of 0.703, which suggesting that the stock is 29.654% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.431, suggesting its more volatile than the S&P 500 by 43.081%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $65M, which are larger than Ocular Therapeutix quarterly revenues of $10.7M. Esperion Therapeutics's net income of -$40.5M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.93x versus 31.97x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -62.24% compared to Esperion Therapeutics's net margin of --. Esperion Therapeutics's return on equity of -- beat Plus Therapeutics's return on equity of --.

Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 366.59%. On the other hand Plus Therapeutics has an analysts' consensus of $9.17 which suggests that it could grow by 2293.39%. Given that Plus Therapeutics has higher upside potential than Esperion Therapeutics, analysts believe Plus Therapeutics is more attractive than Esperion Therapeutics.

Esperion Therapeutics has a beta of 0.703, which suggesting that the stock is 29.654% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.693, suggesting its less volatile than the S&P 500 by 30.722%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $65M, which are larger than Plus Therapeutics quarterly revenues of --. Esperion Therapeutics's net income of -$40.5M is lower than Plus Therapeutics's net income of -$17.4M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.93x versus 0.63x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.